Medicinrådet Secures DKK 8 Million Framework for Real-World Data Consultancy Services

A framework agreement for consultancy services for data and data analysis to support follow-up on Medicinrådet's recommendations worth up to DKK 8 million has been awarded by Medicinrådet. The contract, won by the consortium "Danish Alliance for Real-World Evidence" comprising Region Hovedstaden, Region Midtjylland, and Syddansk Universitet, demonstrates how Denmark is strengthening the use of health data to evaluate the real-world effectiveness of cancer treatments following recommendations.

Introduction

Every cancer patient in Denmark deserves access to effective treatments, and every new medicine should be evaluated based on its real-world performance. The Danish Medicine Council (Medicinrådet) has taken a significant step to strengthen the use of health data in evaluating cancer treatments by awarding a new framework agreement for consultancy services for data and data analysis.

While not a headline-grabbing consumer deal, this contract is fundamental to ensuring that cancer treatments are evaluated based on their effectiveness in Danish clinical practice. It reveals a great deal about how Denmark is leveraging real-world data (RWD) to improve health outcomes and support evidence-based decision-making in healthcare.

Why This Contract Matters

The Danish Medicine Council (Medicinrådet) is responsible for recommending which new medicines should be used as standard treatment in Denmark. The Council's recommendations are based on clinical trials, but real-world data (RWD) – data from actual clinical practice – provides valuable insights into how treatments perform in real-life settings.

A partnership established under the Cancer Plan V and the 2026 Finance Agreement aims to strengthen the use of health data in the uptake of new cancer medicines and to create knowledge about the effectiveness of new medicines after recommendation. This framework agreement supports this partnership by providing consultancy services for pilot projects and the development of a model for follow-up on Medicinrådet's recommendations using RWD.

Contract Timeline

• Previous notice referenced: 138824-2026
• Contract award notice published: 28 July 2026 (OJ S 143/2026)
• Contract concluded: 2 July 2026

Contract Overview

Medicinrådet conducted an open procedure for a framework agreement for consultancy services for data and data analysis to support follow-up on the Council's recommendations. The contract covers consultancy assistance for the implementation of pilot projects and support for the development of a model for follow-up on Medicinrådet's recommendations using real-world data (RWD).

The estimated value of the framework is DKK 5,000,000, with a maximum value of DKK 8,000,000. The contract duration is 48 months. The framework is a single-supplier framework without reopening of competition. The procurement received seven tenders, with the consortium "Danish Alliance for Real-World Evidence" selected as the winner.

Key Contract Details

Detail	Information
Contracting Authority	Medicinrådet (Danish Medicine Council)
Winning Bidder	Danish Alliance for Real-World Evidence (Region Hovedstaden, Region Midtjylland, Syddansk Universitet)
Contract Subject	Research and development consultancy services (CPV 73200000), Health services (CPV 85100000), Counselling services (CPV 85312320)
Procedure Type	Open procedure
Legal Basis	Directive 2014/24/EU, Danish Public Procurement Act
Estimated Value (ex-VAT)	DKK 5,000,000.00
Maximum Framework Value	DKK 8,000,000.00
Tender Value	DKK 6,537,520.00
Contract Duration	48 Months
Award Criteria	Quality (60%), Price (40%)
Bids Received	7
EU Funding	None disclosed
Covered by GPA	Yes
Review Organisation	Klagenævnet for Udbud

Project Scope

The framework agreement covers consultancy services for data and data analysis to support follow-up on Medicinrådet's recommendations. The scope includes:

• Pilot Projects: Consultancy assistance for the implementation of two pilot projects in 2026 to develop and test models for the use of Danish real-world data (RWD) for follow-up on Medicinrådet's recommendations.
• Model Development: Support for the development of a reusable and scalable model for the use of real-world data in follow-up on Medicinrådet's recommendations, which can be implemented in the Danish healthcare system.
• Additional Pilot Projects: Support for further pilot projects during the framework's duration.
• RWD Analysis: Analysis of real-world data to evaluate the effectiveness, safety, and use of cancer treatments after recommendation.
• Partnership Support: Support for the partnership established under Cancer Plan V and the 2026 Finance Agreement.

About the Contracting Authority

Medicinrådet (the Danish Medicine Council) is a public body responsible for recommending which new medicines should be used as standard treatment in Denmark. The Council's recommendations are based on clinical trials and health economic analyses. The Council is a public undertaking controlled by a central government authority, based in Copenhagen.

About the Winning Consortium

The winning bidder is the consortium "Danish Alliance for Real-World Evidence", consisting of three partners:

• Region Hovedstaden (Capital Region of Denmark) – a large public healthcare region, through its Copenhagen Phase IV Unit.
• Region Midtjylland (Central Denmark Region) – a large public healthcare region, through Aarhus University Hospital's Department of Clinical Epidemiology.
• Syddansk Universitet (University of Southern Denmark) – a large university, through its Department of Health Services Research.

The consortium brings together leading expertise in clinical epidemiology, health services research, and real-world data analysis from three of Denmark's key healthcare and academic institutions.

Procurement Analysis

Procedure: An open procedure was used, following the Danish Public Procurement Act. Seven tenders were received, all submitted electronically.

Competition: Seven bids were received, indicating strong competition in the Danish health data consultancy market. Bids came from a range of organisations, including four SMEs and one from another EEA country.

Award Criteria:

• Quality (60%): The quality of the proposed approach, including methodology, expertise, and understanding of the project requirements.
• Price (40%): The total cost of the services.

Quality Emphasis: The 60% weighting for quality reflects the critical importance of expertise, methodological rigour, and understanding of the healthcare data landscape in real-world evidence consultancy. The quality of the analysis is essential for producing reliable evidence to support healthcare decisions.

Framework Structure: The agreement is a single-supplier framework without reopening of competition, meaning that Medicinrådet can directly call off consultancy services against the framework terms for the duration of the contract.

GPA Status: The procurement is covered by the World Trade Organization's Government Procurement Agreement (GPA), meaning it was, in principle, open to qualifying international bidders.

Additional Procurement Facts

• Seven tenders were received, all submitted electronically.
• The framework has a maximum value of DKK 8 million and an estimated value of DKK 5 million.
• Quality is weighted at 60%, price at 40%.
• The winning consortium consists of Region Hovedstaden, Region Midtjylland, and Syddansk Universitet.
• The contract supports the Cancer Plan V and the 2026 Finance Agreement.
• No EU funding was used for this procurement.
• Disputes or review requests fall to the Klagenævnet for Udbud (Public Procurement Complaints Board).

Market & Industry Perspective

The health data consultancy market in Denmark is growing, driven by the increasing use of real-world data in healthcare decision-making. The seven bids received for this contract reflect strong competition and interest in this emerging field.

The 60/40 quality/price weighting reflects the importance of expertise, methodological rigour, and understanding of the healthcare data landscape in real-world evidence consultancy. The quality of the analysis is essential for producing reliable evidence to support healthcare decisions.

The consortium approach, bringing together clinical epidemiology, health services research, and real-world data analysis expertise from three leading institutions, demonstrates the importance of multi-disciplinary collaboration in this field.

Economic Significance

At up to DKK 8 million over 48 months, this framework agreement represents a significant investment in real-world evidence infrastructure for cancer treatment evaluation. The contract ensures that Medicinrådet can access the expertise needed to evaluate the real-world effectiveness of cancer treatments and support evidence-based decision-making.

For the consortium partners, the framework provides a stable, multi-year revenue stream and the opportunity to contribute to the development of real-world evidence methods in Denmark.

Future Procurement Opportunities

This framework agreement covers real-world evidence consultancy through approximately 2030. Related procurement opportunities may include:

• Health data analysis and epidemiology services
• Clinical trial and real-world evidence services
• Health technology assessment services
• Pharmacoepidemiology and drug safety services

Opportunities for Suppliers

Health data consultancy providers active in the Danish public sector should note the emphasis on quality (60%) over price (40%) in this framework. Suppliers must demonstrate strong methodological expertise, understanding of healthcare data, and experience in real-world evidence to compete successfully.

Key success factors include: proven expertise in real-world data analysis, methodological rigour, understanding of the Danish healthcare system and data sources, and strong multi-disciplinary capabilities.

What Businesses Should Watch

• Similar health data and real-world evidence opportunities from other Danish public bodies.
• The evolution of real-world evidence requirements in healthcare decision-making.
• Opportunities for subcontracting with the consortium partners.
• The development of Danish health data infrastructure and access.

DenmarkTender Procurement Intelligence

This contract is a useful case study in how Denmark is strengthening the use of real-world data in healthcare decision-making. Medicinrådet has secured a DKK 8 million framework for real-world evidence consultancy, with the consortium "Danish Alliance for Real-World Evidence" selected through a quality-focused open procedure.

The most notable feature of this tender is the 60% weighting for quality, which reflects the critical importance of expertise, methodological rigour, and understanding of the healthcare data landscape in real-world evidence consultancy. The quality of the analysis is essential for producing reliable evidence to support healthcare decisions. This approach recognises that the value of accurate, reliable real-world evidence far exceeds the cost of the analysis.

The consortium structure of the winning bidder (Region Hovedstaden, Region Midtjylland, and Syddansk Universitet) brings together leading expertise in clinical epidemiology, health services research, and real-world data analysis from three of Denmark's key healthcare and academic institutions. This multi-disciplinary approach is essential for addressing the complex challenges of real-world evidence generation.

The seven bids received reflect strong competition and interest in this emerging field, demonstrating that there is significant capacity in the Danish health data consultancy market.

For suppliers, the lesson is that methodological expertise, understanding of healthcare data, and multi-disciplinary capabilities are essential for real-world evidence consultancy. Organisations that can demonstrate these capabilities are well-positioned for these contracts.

Supplier Takeaways

• Quality is the dominant factor (60% weighting).
• Methodological expertise and rigour are essential.
• Understanding of the Danish healthcare system and data sources is critical.
• Multi-disciplinary capabilities are highly valued.
• Price (40%) is important but secondary to quality.
• Strong competition (7 bids) requires differentiation on quality.

Key Takeaways

• Medicinrådet awarded a DKK 8 million framework for real-world data consultancy to the consortium "Danish Alliance for Real-World Evidence".
• The contract supports the evaluation of cancer treatment effectiveness using real-world data.
• Award criteria: Quality (60%), Price (40%).
• Seven bids were received, with a consortium of public healthcare regions and a university winning.
• Contract duration: 48 Months.
• The framework supports the Cancer Plan V and the 2026 Finance Agreement.

Conclusion

This is not a contract that will make national headlines, but it reflects something structurally important about how Denmark is strengthening the use of real-world data in healthcare decision-making. By awarding a DKK 8 million framework for real-world evidence consultancy to the consortium "Danish Alliance for Real-World Evidence", Medicinrådet ensures that cancer treatments can be evaluated based on their effectiveness in Danish clinical practice. The contract demonstrates the importance of quality, methodological rigour, and multi-disciplinary collaboration in real-world evidence generation, and the value of investing in robust evidence to support healthcare decisions.

Frequently Asked Questions

Q: What is Medicinrådet?

It is the Danish Medicine Council, responsible for recommending which new medicines should be used as standard treatment in Denmark.

Q: What is real-world data (RWD)?

It is data from actual clinical practice, as opposed to data from controlled clinical trials. RWD provides insights into how treatments perform in real-life settings.

Q: What does this framework cover?

It covers consultancy services for data and data analysis to support follow-up on Medicinrådet's recommendations, including pilot projects and model development using real-world data.

Q: Who is the winning bidder?

The consortium "Danish Alliance for Real-World Evidence", consisting of Region Hovedstaden, Region Midtjylland, and Syddansk Universitet.

Q: Is this contract funded by the EU?

No. The notice confirms the project is not financed with EU funds, though it is governed by EU Directive 2014/24/EU.

Source: EU Official Journal, Contract Award Notice 522611-2026, OJ S 143/2026, published 28 July 2026.